Insulin analogs and cancer

Area of Science:

• Endocrinology
• Pharmacology
• Oncology

Background:

• Insulin analogs are widely used for diabetes management, aiming for more physiological insulin replacement.
• Modifications to human insulin create analogs with altered pharmacokinetic and pharmacodynamic profiles.
• A key concern is whether insulin analogs possess increased mitogenic activity, potentially promoting tumor proliferation.

Purpose of the Study:

• To investigate the molecular and biological effects of insulin analogs compared to human insulin.
• To assess the potential for insulin analogs to promote tumor proliferation.
• To evaluate the differential effects of rapid-acting versus long-acting insulin analogs.

Main Methods:

• In vitro studies examining receptor binding and intracellular signaling pathways (e.g., IGF-1R, ERK, PKB/AKT).
• Comparison of molecular and biological effects between insulin, rapid-acting analogs (lispro, aspart, glulisine), and long-acting analogs (glargine, detemir).
• Review of retrospective epidemiological studies on cancer risk associated with insulin analog use.

Main Results:

• Short-acting insulin analogs showed effects similar to human insulin in vitro.
• Long-acting analogs (glargine, detemir) demonstrated decreased insulin receptor binding but increased IGF-1 receptor binding.
• Long-acting analogs exhibited prevalent ERK pathway activation and increased mitogenic effects compared to human insulin in vitro.

Conclusions:

• Long-acting insulin analogs may have distinct molecular and biological effects, including increased mitogenic potential, compared to human insulin and short-acting analogs.
• Retrospective studies suggest a possible increased cancer risk with long-acting analogs, but results are controversial and require stronger evidence.
• Prospective clinical studies are essential to definitively evaluate the tumor growth-promoting effects of long-acting insulin analogs.